Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer Therapies

Inclusion Criteria: * Patient \> 18 years old * Patient naive from anti-EGFR treatment (gefitinib, erlotinib, afatinib, cetuximab panitumumab, osimertinib, alectinib et crizotinib, etc). * NSCLC (non-small cell lung cancer) patients eligible to anti-EGFR as first line treatment (gefitinib, erlotinib,afatinib, etc) * Colorectal cancer patients eligible to anti-EGFR as first line treatment (cetuximab, panitumumab,….) * Head and Neck/ENT (Ear, Nose Troat) cancer patients eligible to anti-EGFR as first line treatment (cetuximab,…) * Signed informed consent * Social security affiliation Exclusion Criteria: * Pregnant or Breastfeeding patient * Patient in age to procreate without an efficient contraceptive method * Patient with previous experience of allergic or irritative contact dermatitis to components of the studied product * Patient with dermatologic conditions that cannot permit the study of skin toxicity of anti-EGFR * Patients under radiotherapy 8 days prior the inclusion date * Patient under immunotherapy 8 days prior the inclusion date * Patient with local or systemic antibiotic treatment for acne 8 days prior the inclusion date * Patient with antihistamines treatment 8 days prior the inclusion date * Patients taking NSAIDs or corticoids as chronic medication or that took NSAIDs or corticoids 5 days prior the inclusion date * Participation to another interventional study * Patient with an altered ECOG (Eastern Cooperative Oncology Group) state ( \>2) * Patient deprived of liberty or subjected to guardianship * Impossibility to track and follow patient for geographical, social or psychiatric reasons.